Рет қаралды 5,612
The first vaccine targeting respiratory syncytial virus (RSV) was just approved for use in the United States. The vaccine is made by GSK, under the name Arexvy, and is for use in individuals 60 years of age+. Older adults are at particular risk for severe disease and death caused by RSV. This approval highlights a critical milestone in public health efforts to combat the prevention of lower respiratory tract disease.